- Report
- November 2023
- 250 Pages
Global
From €2351EUR$2,450USD£2,033GBP
- Report
- January 2024
- 200 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- February 2024
- 118 Pages
Global
From €4558EUR$4,750USD£3,941GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €2399EUR$2,500USD£2,074GBP
- Report
- January 2024
- 250 Pages
Global
From €7628EUR$7,950USD£6,596GBP
- Report
- February 2023
- 143 Pages
North America
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- February 2023
- 128 Pages
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- October 2018
- 17 Pages
Global
From €9595EUR$10,000USD£8,297GBP
- Report
- October 2018
- 18 Pages
Global
From €9595EUR$10,000USD£8,297GBP
- Report
- October 2018
- 15 Pages
Global
From €9595EUR$10,000USD£8,297GBP
- Report
- October 2018
- 20 Pages
Global
From €9595EUR$10,000USD£8,297GBP
- Report
- October 2018
- 17 Pages
Global
From €9595EUR$10,000USD£8,297GBP
Selexipag is a drug used to treat pulmonary arterial hypertension (PAH), a type of cardiovascular disease. It is a selective prostacyclin receptor agonist, meaning it works by stimulating the prostacyclin receptor to reduce the pressure in the pulmonary arteries. Selexipag is taken orally and is available in tablet form. It is typically prescribed in combination with other drugs to treat PAH.
Selexipag is approved for use in the United States, Europe, and other countries. It is marketed by Actelion Pharmaceuticals, a subsidiary of Johnson & Johnson, and is available in several countries. Other companies that produce and market selexipag include United Therapeutics Corporation, GlaxoSmithKline, and Bayer AG. Show Less Read more
